New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
07:52 EDTQLTI, AUXLAuxilium move to Canada may up odds of acquisition, says MKM Partners
MKM Partners believes Auxilium's (AUXL) merger with QLT Inc. (QLTI), which will allow it to move its domicile to Canada, may increases the chances that the company could be acquired, as a future buyer could avoid new U.S. laws that discourage inversions, if those laws are passed. The firm reiterates its Buy rating and $26 price target on Auxilium.
News For AUXL;QLTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:35 EDTAUXLBioSpecifics announces new data on XIAFLEX for Peyronie's Disease
Subscribe for More Information
November 20, 2014
07:09 EDTAUXLAuxilium presents STENDRA data at SMSNA meeting
Auxilium Pharmaceuticals announced that data were presented regarding the use of STENDRA tablets for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. A post-hoc analysis of data from a placebo-controlled, Phase 4 study of STENDRA evaluated men who had at least one attempt at intercourse within approximately 15 minutes of taking the medication. The STENDRA 100 and 200mg doses demonstrated statistically significant improvement in onset of erectogenic effect at approximately 15 minutes compared to placebo, with a mean per-patient proportion of sexual attempts that resulted in at least one successful intercourse within approximately 15 minutes after dosing of 73.3% and 71.5%, respectively. Results of a study examining the proportion of men with ED who reported successful intercourse within the first three doses of STENDRA showed more than 60% of patients reported successful intercourse within the first three doses of STENDRA. This compares to about 40% with placebo. A higher percentage, or 75% for STENDRA vs. 56% for placebo, also reported success after any dose.
07:07 EDTAUXLAuxilium presents XIAFLEX for Peyronie's Disease data
Auxilium Pharmaceuticals announced presentations of data from new studies, as well as new analyses of data from the Phase 2 and the pivotal Phase 3 IMPRESS trials evaluating XIAFLEX for the treatment of Peyronie's disease, at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. Data were presented providing further evidence that PD bother is clinically significant and may be a useful measure in clinical practice when treating PD. Data were also presented suggesting that improvements in PD bother are correlated with improvements in penile curvature deformity.
November 19, 2014
07:33 EDTAUXLEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
November 18, 2014
07:02 EDTAUXLAntares Pharma names James Fickenscher as SVP, CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use